Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' KYRLE PA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 67 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Rintelen, C; Pabinger, I; Bettelheim, P; Lechner, K; Kyrle, PA; Knobl, P; Schneider, B; Mannhalter, C
      Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation

      EUROPEAN JOURNAL OF HAEMATOLOGY
    2. Endler, G; Kyrle, PA; Eichinger, S; Exner, M; Mannhalter, C
      Multiplexed mutagenically separated PCR: Simultaneous single-tube detection of the factor V R506Q (G1691A), the prothrombin G20210A, and the methylenetetrahydrofolate reductase A223V (C67TT) variants

      CLINICAL CHEMISTRY
    3. Kyrle, PA; Minar, E; Hirschl, M; Bialonczyk, C; Stain, M; Schneider, B; Weltermann, A; Speiser, W; Lechner, K; Eichinger, S
      High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.

      NEW ENGLAND JOURNAL OF MEDICINE
    4. Kyrle, PA; Eichinger, S
      High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. Reply

      NEW ENGLAND JOURNAL OF MEDICINE
    5. Eichinger, S; Kyrle, PA; Pabinger, I; Lechner, K
      The risk of recurrent venous thromboembolic disease - implications for treatment

      ACUTE PULMONARY EMBOLISM
    6. Weltermann, A; Wolzt, M; Petersmann, K; Czerni, C; Graselli, U; Lechner, K; Kyrle, PA
      Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    7. Rintelen, C; Mannhalter, C; Lechner, K; Eichinger, S; Kyrle, PA; Papagiannopoulos, M; Schneider, B; Pabinger, I
      No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene

      BLOOD COAGULATION & FIBRINOLYSIS
    8. Eichinger, S; Weltermann, A; Philipp, K; Hafner, E; Kaider, A; Kittl, EM; Brenner, B; Mannhalter, C; Lechner, K; Kyrle, PA
      Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden

      THROMBOSIS AND HAEMOSTASIS
    9. Eichinger, S; Minar, E; Hirschl, M; Bialonczyk, C; Stain, M; Mannhalter, C; Stumpflen, A; Schneider, B; Lechner, K; Kyrle, PA
      The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene

      THROMBOSIS AND HAEMOSTASIS
    10. Quehenberger, P; Handler, S; Mannhalter, C; Kyrle, PA; Speiser, W
      The Factor V (Leiden) Test: Evaluation of an assay based on dilute RussellViper Venom Time for the detection of the Factor V Leiden mutation

      THROMBOSIS RESEARCH
    11. Male, C; Lechner, K; Eichinger, S; Kyrle, PA; Kapiotis, S; Wank, H; Kaider, A; Pabinger, I
      Clinical significance of lupus anticoagulants in children

      JOURNAL OF PEDIATRICS
    12. KYRLE PA; MANNHALTER C; BEGUIN S; STUMPFLEN A; HIRSCHL M; WELTERMANN A; STAIN M; BRENNER B; SPEISER W; PABINGER I; LECHNER K; EICHINGER S
      CLINICAL-STUDIES AND THROMBIN GENERATION IN PATIENTS HOMOZYGOUS OR HETEROZYGOUS FOR THE G20210A MUTATION IN THE PROTHROMBIN GENE

      Arteriosclerosis, thrombosis, and vascular biology
    13. WELTERMANN A; EICHINGER S; KYRLE PA
      A NOVEL IMMUNOASSAY FOR THE QUANTIFICATION OF HUMAN TISSUE FACTOR-BINDING TO ACTIVATED FACTOR-VII

      Blood coagulation & fibrinolysis
    14. MUSTAFA S; MANNHALTER C; RINTELEN C; KYRLE PA; KNOBL P; LECHNER K; PABINGER I
      CLINICAL-FEATURES OF THROMBOPHILIA IN FAMILIES WITH GENE DEFECTS IN PROTEIN-C OR PROTEIN-S COMBINED WITH FACTOR-V-LEIDEN

      Blood coagulation & fibrinolysis
    15. FUREDER W; KYRLE PA; GISSLINGER H; LECHNER K
      LOW-MOLECULAR-WEIGHT HEPARIN-INDUCED SKIN NECROSIS

      Annals of hematology
    16. WELTERMANN A; PABINGER I; GEISSLER K; JAGER U; GISSLINGER H; KNOBL P; EICHINGER S; KYRLE PA; VALENT P; SPEISER W; SCHWARZINGER I; MANNHALTER C; LECHNER K
      HYPOFIBRINOGENEMIA IN NON-M3 ACUTE MYELOID-LEUKEMIA - INCIDENCE, CLINICAL AND LABORATORY CHARACTERISTICS AND PROGNOSIS

      Leukemia
    17. EICHINGER S; STUMPFLEN A; HIRSCHL M; BIALONCZYK C; HERKNER K; STAIN M; SCHNEIDER B; PABINGER I; LECHNER K; KYRLE PA
      HYPERHOMOCYSTEINEMIA IS A RISK FACTOR OF RECURRENT VENOUS THROMBOEMBOLISM

      Thrombosis and haemostasis
    18. FURLAN M; ROBLES R; GALBUSERA M; REMUZZI G; KYRLE PA; BRENNER B; KRAUSE M; SCHARRER I; AUMANN V; MITTLER U; SOLENTHALER M; LAMMLE B
      VON-WILLEBRAND FACTOR-CLEAVING PROTEASE IN THROMBOTIC THROMBOCYTOPENIC PURPURA AND THE HEMOLYTIC-UREMIC SYNDROME

      The New England journal of medicine
    19. GASIC S; EICHLER HG; KYRLE PA; WOLZT M; EIDENBERGER T; VIERHAPPER H
      THROMBOXANE A(2) DOES NOT MEDIATE ANGIOTENSIN II-DEPENDENT NONISCHEMIC PERIPHERAL VASOCONSTRICTION IN HEALTHY-MEN - A PILOT-STUDY

      International journal of clinical pharmacology and therapeutics
    20. KYRLE PA; STUMPFLEN A; HIRSCHL M; BIALONCZYK C; HERKNER K; SPEISER W; WELTERMANN A; KAIDER A; PABINGER I; LECHNER K; EICHINGER S
      LEVELS OF PROTHROMBIN FRAGMENT F1+2 IN PATIENTS WITH HYPERHOMOCYSTEINEMIA AND A HISTORY OF VENOUS THROMBOEMBOLISM

      Thrombosis and haemostasis
    21. WOLZT M; EDER M; WELTERMANN A; ENTLICHER J; EICHLER HG; KYRLE PA
      COMPARISON OF THE EFFECTS OF DIFFERENT LOW-MOLECULAR-WEIGHT HEPARINS ON THE HEMOSTATIC SYSTEM ACTIVATION IN-VIVO IN MAN

      Thrombosis and haemostasis
    22. KYRLE PA; EICHINGER S; PABINGER I; STUMPFLEN A; HIRSCHL M; BIALONCZYK C; SCHNEIDER B; MANNHALTER C; MELICHART M; TRAXLER G; WELTERMANN A; SPEISER W; LECHNER K
      PROTHROMBIN FRAGMENT F1+2 IS NOT PREDICTIVE FOR RECURRENT VENOUS THROMBOEMBOLISM

      Thrombosis and haemostasis
    23. EICHINGER S; PABINGER I; STUMPFLEN A; HIRSCHL M; BIALONCZYK C; SCHNEIDER B; MANNHALTER C; MINAR E; LECHNER K; KYRLE PA
      THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH AND WITHOUT FACTOR-V-LEIDEN

      Thrombosis and haemostasis
    24. KYRLE PA; BROCKMEIER J; WELTERMANN A; EICHINGER S; SPEISER W; LECHNER K; EICHLER HG
      INHIBITION RATHER THAN ENHANCEMENT OF HEMOSTATIC SYSTEM ACTIVATION DURING INITIATION OF ORAL ANTICOAGULANT TREATMENT

      Thrombosis and haemostasis
    25. EICHINGER S; STUMPFLEN A; HIRSCHL M; BIALONCZYK C; PABINGER I; HERKNER K; SCHNEIDER B; LECHNER K; KYRLE PA
      HYPERHOMOCYSTEINEMIA (H-HC) IS A RISK FACTOR OF RECURRENT VENOUS THROMBOEMBOLISM (VTE) IN MALE-PATIENTS

      Thrombosis and haemostasis
    26. MALE C; KAPIOTIS S; EICHINGER S; KYRLE PA; LECHNER K
      CLINICAL-SIGNIFICANCE AND COURSE OF LUPUS ANTICOAGULANTS IN CHILDREN

      Thrombosis and haemostasis
    27. WELTERMANN A; KYRLE PA; EICHINGER S
      QUANTIFICATION OF HUMAN TISSUE FACTOR (TF) BINDING TO RECOMBINANT FACTOR VIIA (RVIIA)

      Thrombosis and haemostasis
    28. KYRLE PA; CHESEBRO JH; FUSTER V; RUBSAMEN K; BADIMON JJ
      ANTITHROMBOTIC EFFECTS OF PEG-HIRUDIN, A NEW AND LONG-LASTING THROMBIN INHIBITOR, IN HUMANS

      Thrombosis and haemostasis
    29. KYRLE PA; EICHINGER S; STUMPFLEN A; HIRSCHL M; BIALONCZYK C; HERKNER K; PABINGER I; SPEISER W; SCHNEIDER B; LECHNER K
      HEMOSTATIC SYSTEM ACTIVATION IN PATIENTS WITH HYPERHOMOCYSTEINEMIA (H-HC)

      Thrombosis and haemostasis
    30. RINTELEN C; PABINGER I; LECHNER K; EICHINGER S; KYRLE PA; MANNHALTER C
      NO EVIDENCE FOR AN INCREASE OF THE RISK OF VENOUS THROMBOSIS IN PATIENTS WITH FACTOR-V-LEIDEN BY THE HOMOZYGOUS MUTATION IN THE METHYLENETETRAHYDROFOLATE REDUCTASE GENE

      Thrombosis and haemostasis
    31. EICHINGER S; BRENNER B; PHILIPP K; PUTZ M; SCHUCHTER K; BAUER K; KITTL E; KAIDER A; WELTERMANN A; LECHNER K; KYRLE PA
      MARKED COAGULATION ACTIVATION DURING PREGNANCY WITHOUT EVIDENCE OF VENOUS THROMBOEMBOLISM (VTE)

      Thrombosis and haemostasis
    32. RINTELEN C; SCHARRER I; KLINKE S; MANNHALTER C; EICHINGER S; KYRLE PA; LECHNER K; PABINGER I
      HIGH PREVALENCE OF STILLBIRTHS IN WOMEN HOMOZYGOUS FOR FACTOR-V-LEIDEN MUTATION

      Thrombosis and haemostasis
    33. MUHM M; CLAEYS L; HUK I; KOPPENSTEINER R; KYRLE PA; MINAR E; STUMPFLEN A; EHRINGER H; POLTERAUER P
      THROMBOEMBOLIC COMPLICATIONS IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) SHOWING CROSS-REACTIVITY TO A LOW-MOLECULAR-WEIGHT HEPARIN - TREATMENT WITH ORG-10172 (LOMOPARAN)

      Wiener Klinische Wochenschrift
    34. KYRLE PA; CHESEBRO JH; HAYES RM; RUBSAMEN K; FUSTER V; BADIMON JJ
      ANTITHROMBOTIC EFFECT OF PEG-HIRUDIN COMPARED TO HEPARIN AND HEPARIN PLUS C7E3

      Circulation
    35. WELTERMANN A; KYRLE PA
      LABORATORY STUDIES ON THE RELIABILITY OF A COMMERCIAL IMMUNOASSAY FORTHROMBIN-ANTITHROMBIN COMPLEXES

      Blood coagulation & fibrinolysis
    36. THALHAMMER F; GEISSLER K; JAGER U; KYRLE PA; PABINGER I; MITTERBAUER M; GISSLINGER H; KNOBL P; LACZIKA K; SCHNEIDER B; HAAS OA; LECHNER K
      DURATION OF 2ND COMPLETE REMISSION IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA TREATED WITH CHEMOTHERAPY - A RETROSPECTIVE SINGLE-CENTER STUDY

      Annals of hematology
    37. MELICHART M; KYRLE PA; EICHINGER S; RINTELEN C; MANNHALTER C; PABINGER I
      THROMBOTIC TENDENCY IN 75 SYMPTOMATIC, UNRELATED PATIENTS WITH APC RESISTANCE

      Wiener Klinische Wochenschrift
    38. WAGNER B; FASCHING P; SCHNEIDER B; KURZEMANN S; WALDHAUS W; LECHNER K; KYRLE PA
      PLATELET AND ENDOTHELIAL-CELL FUNCTION IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS WITH EXCELLENT, GOOD, OR POOR METABOLIC CONTROL

      Microvascular research
    39. JILMA B; EICHLER HG; VONDROVEC B; BREITENEDER H; KYRLE PA; KITZWEGER E; KAPIOTIS S; SPEISER W
      EFFECTS OF DESMOPRESSIN ON CIRCULATING P-SELECTIN

      British Journal of Haematology
    40. RINTELEN C; PABINGER I; LECHNER K; EICHINGER S; KYRLE PA; MANNHALTER C
      HOMOZYGOUS C-]T MUTATION IN THE METHYLENE TETRAHYDROFOLATE REDUCTASE (MTHFR) GENE DOES NDT INCREASE THE RISK FOR VENOUS THROMBOSIS IN PATIENTS WITH THE FACTOR-V LEIDEN MUTATION

      Blood
    41. EICHINGER S; WOLZT M; SCHNEIDER B; NIESZPAURLOS M; HEINRICHS H; LECHNER K; EICHLER HG; KYRLE PA
      EFFECTS OF RECOMBINANT HIRUDIN (R-HIRUDIN, HBW-023) ON COAGULATION AND PLATELET ACTIVATION IN-VIVO - COMPARISON WITH UNFRACTIONATED HEPARINAND A LOW-MOLECULAR-WEIGHT HEPARIN PREPARATION (FRAGMIN)

      Arteriosclerosis, thrombosis, and vascular biology
    42. KREJCY K; SCHMETTERER L; KASTNER J; NIESZPAURLOS M; MONITZER B; SCHUTZ W; EICHLER HG; KYRLE PA
      ROLE OF NITRIC-OXIDE IN HEMOSTATIC SYSTEM ACTIVATION IN-VIVO IN HUMANS

      Arteriosclerosis, thrombosis, and vascular biology
    43. KREJCY K; SCHMETTERER L; KASTNER J; EICHLER HG; KYRLE PA
      EFFECTS OF NITRIC-OXIDE (NO) - INHALATION OR INHIBITION OF NO SYNTHESIS BY INFUSION OF NG-MONOMETHYL-L-ARGININE (L-NMMA) ON HEMOSTATIC SYSTEM ACTIVATION IN-VIVO IN MAN

      Thrombosis and haemostasis
    44. PABINGER I; MUSTAFA S; RINTELEN C; KYRLE PA; LECHNER K; MANNHALTER C
      FACTOR-V (FV) LEIDEN MUTATION (APC-RESISTANCE) INCREASES THE RISK FORVENOUS THROMBOEMBOLISM IN PATIENTS WITH A GENE DEFECT OF THE PROTEIN-C (PC) OR PROTEIN-S (PS) GENE

      Thrombosis and haemostasis
    45. LECHNER K; KYRLE PA
      ANTITHROMBIN-III CONCENTRATES - ARE THEY CLINICALLY USEFUL

      Thrombosis and haemostasis
    46. WOLZT M; WELTERMANN A; NIESZPAURLOS M; SCHNEIDER B; FASSOLT A; LECHNER K; EICHLER HG; KYRLE PA
      STUDIES ON THE NEUTRALIZING EFFECTS OF PROTAMINE ON UNFRACTIONATED AND LOW-MOLECULAR-WEIGHT HEPARIN (FRAGMIN(R)) AT THE SITE OF ACTIVATION OF THE COAGULATION SYSTEM IN MAN

      Thrombosis and haemostasis
    47. KALHS P; BRUGGER S; SCHWARZINGER I; GREINIX HT; KEIL F; KYRLE PA; KNOBL P; SCHNEIDER B; HOCKER P; LINKESCH W; LECHNER K
      MICROANGIOPATHY FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION - ASSOCIATION WITH CYCLOSPORINE AND METHYLPREDNISOLONE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS

      Transplantation
    48. BLOCHLDAUM B; PEHAMBERGER H; KURZ C; KYRLE PA; WAGNER O; MULLER M; MONITZER B; EICHLER HG
      EFFECTS OF CISPLATIN ON URINARY THROMBOXANE B-2 EXCRETION

      Clinical pharmacology and therapeutics
    49. EICHINGER S; PABINGER I; STUMPFLEN A; HIRSCHL M; BIALONCZYK C; FORBERG E; SCHNEIDER B; RINTELEN C; LECHNER K; KYRLE PA
      THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM (VTE) AFTER DISCONTINUATION OF ORAL ANTICOAGULANTS (OAC) IN PATIENTS WITHOUT AND WITH FACTOR-V(FV) LEIDEN AND THE PREDICTIVE VALUE OF A MOLECULAR MARKER OF THROMBOSIS

      Blood
    50. SCHERRER R; BETTELHEIM P; GEISSLER K; JAGER U; KNOBL P; KYRLE PA; LACZIKA K; MITTERBAUER G; NEUMANN E; SCHNEIDER B; SCHWARZINGER I; LECHNER K
      HIGH EFFICACY OF THE GERMAN MULTICENTER ALL (GMALL) PROTOCOL FOR TREATMENT OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) - A SINGLE-INSTITUTION STUDY

      Annals of hematology
    51. LACZIKA K; MITTERBAUER G; KORNINGER L; KNOBL P; SCHWARZINGER I; KAPIOTIS S; HAAS OA; KYRLE PA; PONT J; OEHLER L; PURTSCHER B; THALHAMMER F; LECHNER K; JAEGER U
      RAPID ACHIEVEMENT OF PML-RAR-ALPHA POLYMERASE CHAIN-REACTION (PCR)-NEGATIVITY BY COMBINED TREATMENT WITH ALL-TRANS-RETINOIC ACID AND CHEMOTHERAPY IN ACUTE PROMYELOCYTIC LEUKEMIA - A PILOT-STUDY

      Leukemia
    52. EICHINGER S; WOLZT M; NIESZPAURLOS M; SCHNEIDER B; LECHNER K; EICHLER HG; KYRLE PA
      EFFECTS OF A LOW-MOLECULAR-WEIGHT HEPARIN (FRAGMIN(R)) AND OF UNFRACTIONATED HEPARIN ON COAGULATION ACTIVATION AT THE SITE OF PLUG FORMATION IN-VIVO

      Thrombosis and haemostasis
    53. PABINGER I; SCHNEIDER B; SCHARRER I; HACHWUNDERLE V; LECHNER K; EICHINGER S; KYRLE PA; VINAZZER H; LAMMLE B; DEMARMELSBIASIUTTI F; TILSNER V; MARX G; SEIFRIED E; GABELMANN A; ASPOCK G; FISCHER M; HALBMAYER WM
      THROMBOTIC RISK OF WOMEN WITH HEREDITARY ANTITHROMBIN-III-DEFICIENCY,PROTEIN C-DEFICIENCY AND PROTEIN S-DEFICIENCY TAKING ORAL-CONTRACEPTIVE MEDICATION

      Thrombosis and haemostasis
    54. PABINGER I; KYRLE PA; HEISTINGER M; EICHINGER S; WITTMANN E; LECHNER K
      THE RISK OF THROMBOEMBOLISM IN ASYMPTOMATIC PATIENTS WITH PROTEIN-C AND PROTEIN-S DEFICIENCY - A PROSPECTIVE COHORT STUDY

      Thrombosis and haemostasis
    55. CLEMETSON JM; KYRLE PA; BRENNER B; CLEMETSON KJ
      VARIANT BERNARD-SOULIER-SYNDROME-ASSOCIATED WITH A HOMOZYGOUS MUTATION IN THE LEUCINE-RICH DOMAIN OF GLYCOPROTEIN-IX

      Blood
    56. EICHINGER S; WOLZT M; EICHLER HG; HEINRICHS H; LECHNER K; KYRLE PA
      EFFECTS OF RECOMBINANT HIRUDIN (R-HIRUDIN) ON COAGULATION AND PLATELET ACTIVATION IN-VIVO - COMPARISON TO UNFRACTIONATED HEPARIN (UFH) AND LOW-MOLECULAR-WEIGHT HEPARIN (LMWH)

      Blood
    57. KALHS P; BRUGGER S; SCHWARZINGER I; GREINIX HT; KEIL F; KYRLE PA; KNOBL P; LINKESCH W; LECHNER K
      SEVERE MICROANGIOPATHY IN PATIENTS RECEIVING CYCLOSPORINE-A AND METHYLPREDNISOLONE (CSA-MP) FOR GVHD PROPHYLAXIS AFTER ALLOGENEIC MARROW TRANSPLANTATION

      Blood
    58. GSUR A; ZOCHBAUER S; GOTZL M; KYRLE PA; LECHNER K; PIRKER R
      MDR1 RNA EXPRESSION AS A PROGNOSTIC FACTOR IN ACUTE MYELOID-LEUKEMIA - AN UPDATE

      Leukemia & lymphoma
    59. JAEGER U; KAPIOTIS S; PABINGER I; PUCHHAMMER E; KYRLE PA; LECHNER K
      TRANSIENT LUPUS ANTICOAGULANT ASSOCIATED WITH HYPOPROTHROMBINEMIA ANDFACTOR-XII DEFICIENCY FOLLOWING ADENOVIRUS INFECTION

      Annals of hematology
    60. SCHERRER R; GEISSLER K; KYRLE PA; GISSLINGER H; JAGER U; BETTELHEIM P; LACZIKA K; LOCKER G; SCHOLTEN C; SILLABER C; SCHWARZINGER I; THALHAMMER F; LECHNER K
      GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) AS AN ADJUNCT TO INDUCTION CHEMOTHERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)

      Annals of hematology
    61. WILLFORT A; LORBER C; KAPIOTIS S; SERTL S; HAINZ R; KIRCHWEGER P; JAGER U; KYRLE PA; LECHNER K; GEISSLER K
      TREATMENT OF DRUG-INDUCED AGRANULOCYTOSIS WITH RECOMBINANT GRANULOCYTE-COLONY-STIMULATING FACTOR (RH G-CSF)

      Annals of hematology
    62. EICHINGER S; NIESZPAURLOS M; SCHNEIDER B; WOLZT M; PABINGER I; EICHLER HG; LECHNER K; KYRLE PA
      EFFECTS OF LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) AND UNFRACTIONATED HEPARIN (UFH) ON COAGULATION AND PLATELET ACTIVATION AT THE SITE OF PLUG FORMATION

      Thrombosis and haemostasis
    63. KYRLE PA; BRENNER B; MANNHALTER C; SCHERRER R; HAUSER I; DITTRICH C; LECHNER K
      IDENTICAL VON-WILLEBRAND-FACTOR (VWF) MULTIMER ABNORMALITIES IN IDIOPATHIC AND SECONDARY TUMOR-ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)

      Thrombosis and haemostasis
    64. PABINGER L; KYRLE PA; HEISTINGER M; WITTMANN E; LECHNER K
      THE RISK OF THROMBOSIS IN ASYMPTOMATIC PATIENTS WITH HEREDITARY PROTEIN-C OR PROTEIN-S DEFICIENCY - A PROSPECTIVE COHORT STUDY

      Thrombosis and haemostasis
    65. HAUSER I; GISSLINGER H; LOCKER G; ELBL W; KYRLE PA; PABINGER I; LECHNER K
      POSTPARTUM FACTOR-VIII INHIBITORS - REPORT OF 2 CASES WITH SPECIAL REFERENCE TO THE EFFICACY OF VARIOUS TREATMENTS

      Wiener Klinische Wochenschrift
    66. POBER M; KYRLE PA; PANZER S
      GENOTYPING PROVIDES A RELIABLE TOOL FOR THE DETERMINATION OF THE PLATELET ANTIGEN SYSTEM HPA-1 IN GLANZMANN THROMBASTHENIA

      British Journal of Haematology
    67. EICHINGER S; WOLZT M; EICHLER HG; LECHNER K; KYRLE PA
      EFFECTS OF A LOW-MOLECULAR-WEIGHT HEPARIN (LMWH, FRAGMIN(R) AND OF UNFRACTIONATED HEPARIN (UFH) ON COAGULATION AND PLATELET ACTIVATION IN-VIVO

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 19:15:49